Bufalin engages in RIP1-dependent and ROS-dependent programmed necroptosis in breast cancer cells by targeting the RIP1/RIP3/PGAM5 pathway.
Antineoplastic Agents
/ pharmacology
Apoptosis
Biomarkers, Tumor
/ genetics
Breast Neoplasms
/ drug therapy
Bufanolides
/ pharmacology
Cell Proliferation
Female
Gene Expression Regulation, Neoplastic
Humans
Mitochondrial Proteins
/ antagonists & inhibitors
Necroptosis
Nuclear Pore Complex Proteins
/ antagonists & inhibitors
Phosphoprotein Phosphatases
/ antagonists & inhibitors
RNA-Binding Proteins
/ antagonists & inhibitors
Reactive Oxygen Species
/ metabolism
Receptor-Interacting Protein Serine-Threonine Kinases
/ antagonists & inhibitors
Tumor Cells, Cultured
Journal
Anti-cancer drugs
ISSN: 1473-5741
Titre abrégé: Anticancer Drugs
Pays: England
ID NLM: 9100823
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
pubmed:
5
3
2019
medline:
20
9
2020
entrez:
5
3
2019
Statut:
ppublish
Résumé
Breast cancer causes high mortality among females worldwide. Bufalin has recently been shown to trigger tumor cell death, although the mechanism of cytotoxicity remains unclear. The cytotoxicity of bufalin in breast cancer cells was examined using an MTT assay. The modes of death and intracellular reactive oxygen species production were measured by flow cytometry. We also observed cellular morphologic changes by Hoechst 33342 and propidium iodide staining and transmission electron microscopy. Western blotting was performed to determine the expression levels of related proteins. Our results showed that bufalin reduced cellular viability and promoted reactive oxygen species production, which could be inhibited by Nec-1 and N-acetylcysteine. Necroptosis was detected by Hoechst 33342 and propidium iodide staining and transmission electron microscopy. Western blot analysis showed that bufalin induced necroptosis by upregulating the necroptosis mediator RIP1 and the RIP1/RIP3/PGAM5 pathway. Taken together, these findings indicated that bufalin induces breast cancer cell necroptosis by targeting the RIP1/RIP3/PGAM5 pathway.
Identifiants
pubmed: 30829654
doi: 10.1097/CAD.0000000000000770
doi:
Substances chimiques
AGFG1 protein, human
0
Antineoplastic Agents
0
Biomarkers, Tumor
0
Bufanolides
0
Mitochondrial Proteins
0
Nuclear Pore Complex Proteins
0
RNA-Binding Proteins
0
Reactive Oxygen Species
0
RIPK3 protein, human
EC 2.7.11.1
Receptor-Interacting Protein Serine-Threonine Kinases
EC 2.7.11.1
PGAM5 protein, human
EC 3.1.3.16
Phosphoprotein Phosphatases
EC 3.1.3.16
bufalin
U549S98QLW
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM